Underwriting AgreementUnderwriting Agreement • September 12th, 2017 • Incyte Corp • Services-commercial physical & biological research • New York
Incyte Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Merrill Lynch, Pierce, Fenner & Smith Incorporated (the “Underwriter”) an aggregate of 4,945,000 shares (the “Firm Securities”) and, at the election of the Underwriter, up to 741,750 additional shares (the “Optional Securities”) of Common Stock, $.001 par value per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriter elects to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
